SCYX News and Press, SCYNEXIS Inc. From 04/20/22

JERSEY CITY, N.J., April 20, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of interim data from its ongoing Phase 3 FU...

JERSEY CITY, N.J., April 19, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant fungal infections, today announced that BREXAFEMME ® (ibrexafungerp tablet...

FDA approved Pacritinib on Feb 28th, and the stock has appreciated more than 150%. However, the risk-reward has deteriorated significantly since our last article. The company does not have any more short-term catalysts, and considering that Pacritinib is an encumbered asset (deal with...

JERSEY CITY, N.J., April 04, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced participation in three women’s health conference...

SCYNEXIS, Inc. (SCYX) Q4 2021 Earnings Conference Call March 29, 2022, 8:30 AM ET Company Participants Debbie Etchison - Executive Director, Communications Marco Taglietti - President and Chief Executive Officer Christine Coyne - Chief Commercial Officer David Angulo - Chief Medical Officer L...

Gainers: IGM Biosciences (IGMS) +105%. China SXT Pharmaceuticals (SXTC) +73%. Clever Leaves Holdings (CLVR) +42%. MicroVision (MVIS) +31%. LianBio (LIAN) +26%. TC Biopharm (TCBP) +26%. Robinhood Markets (HOOD) +25%. Kinnate Biopharma (KNTE) +24%. Auddia (AUUD) +23%. Molecular Templates (...

Scynexis (SCYX -14.9%) stock declined following its Q4 results. Brexafemme, which was launched in August 2021, generated net revenue of ~$0.6M in Q4 2021. Research and development expenses decreased to $7.69M, compared to $10.16M in Q4 2020. Q4 net loss narrowed to -$29.24M, compared to net l...

SCYNEXIS press release (NASDAQ:SCYX): Q4 GAAP EPS of -$1.05 misses by $0.28. Revenue of $0.6M misses by $0.56M. Cash and cash equivalents totaled $104.5 million on December 31, 2021, compared to $93.0 million in cash, and cash equivalents on December 31, 2020. Based upon its existing operatin...

BREXAFEMME ® (ibrexafungerp tablets), launched in August 2021, achieved net revenues of $1.1 million in 2021. Fourth quarter 2021 net revenues were $0.6 million. As of the end of 2021, BREXAFEMME was covered by commercial insurance plans representing 81 million or 48% of ...

ASO, BGRY, CONN, DPRO, EH, ESLT, HUMA, KALA, LODE, LOVE, MKC, SCYX, UXIN For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings before Tuesday's open